home / stock / glue / glue quote
Last: | $3.93 |
---|---|
Change Percent: | 7.97% |
Open: | $3.73 |
Close: | $3.64 |
High: | $4.36 |
Low: | $3.73 |
Volume: | 119,314 |
Last Trade Date Time: | 07/08/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.93 | $3.73 | $3.64 | $4.36 | $3.73 | 119,314 | 07-08-2024 |
$3.64 | $3.83 | $3.64 | $3.9 | $3.61 | 335,030 | 07-05-2024 |
$3.89 | $3.59 | $3.89 | $3.91 | $3.57 | 158,846 | 07-04-2024 |
$3.89 | $3.59 | $3.89 | $3.91 | $3.57 | 158,846 | 07-03-2024 |
$3.59 | $3.96 | $3.59 | $4.15 | $3.54 | 290,920 | 07-02-2024 |
$3.94 | $3.75 | $3.94 | $4.19 | $3.75 | 402,790 | 07-01-2024 |
$3.74 | $3.32 | $3.74 | $3.74 | $3.21 | 579,360 | 06-28-2024 |
$3.38 | $3.69 | $3.38 | $3.71 | $3.32 | 220,909 | 06-27-2024 |
$3.69 | $3.78 | $3.69 | $3.81 | $3.6 | 204,374 | 06-26-2024 |
$3.79 | $3.85 | $3.79 | $3.88 | $3.63 | 200,213 | 06-25-2024 |
$3.81 | $3.66 | $3.81 | $3.86 | $3.6 | 187,142 | 06-24-2024 |
$3.63 | $3.59 | $3.63 | $3.72 | $3.43 | 922,019 | 06-21-2024 |
$3.56 | $3.52 | $3.56 | $3.6407 | $3.49 | 198,150 | 06-20-2024 |
$3.54 | $3.67 | $3.54 | $3.85 | $3.51 | 200,429 | 06-19-2024 |
$3.54 | $3.67 | $3.54 | $3.85 | $3.51 | 200,429 | 06-18-2024 |
$3.67 | $3.76 | $3.67 | $3.91 | $3.5 | 228,175 | 06-17-2024 |
$3.83 | $3.99 | $3.83 | $4.11 | $3.71 | 283,370 | 06-14-2024 |
$4.01 | $4.15 | $4.01 | $4.24 | $3.98 | 168,274 | 06-13-2024 |
$4.16 | $4.45 | $4.16 | $4.49 | $4.09 | 120,548 | 06-12-2024 |
$4.28 | $3.97 | $4.28 | $4.42 | $3.97 | 147,923 | 06-11-2024 |
News, Short Squeeze, Breakout and More Instantly...
Monte Rosa Therapeutics Inc. Company Name:
GLUE Stock Symbol:
NASDAQ Market:
Monte Rosa Therapeutics Inc. Website:
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside cha...
Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrates favorable safety and pharmacodynamic profile dosing 0.5 mg using a 21/7 schedule; currently assessing 0.75 mg dose level; final determination of recommended Phase 2 dose and updated clinical results anticipated in H2 202...
MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits disease progression, pro-inflammatory cytokines and autoantibody production in a model of rheumatoid arthritis Initiation of MRT-6160 Phase 1 SAD/MAD study anticipated in mid-year 2024 with initial clinical data expected ...